Advertisement

Annals of Surgical Oncology

, Volume 23, Issue 13, pp 4344–4351 | Cite as

Sex Disparity in Gastric Cancer: Female Sex is a Poor Prognostic Factor for Advanced Gastric Cancer

  • Hae Won Kim
  • Jie-Hyun KimEmail author
  • Beom Jin LimEmail author
  • HyunKi Kim
  • Hoguen Kim
  • Jae Jun Park
  • Young Hoon Youn
  • Hyojin Park
  • Sung Hoon Noh
  • Jong Won Kim
  • Seung Ho Choi
Gastrointestinal Oncology

Abstract

Background

The overall incidence of gastric cancer (GC) is higher in males than females. Specifically, signet ring cell carcinoma (SRC) is more frequently observed in younger female patients. However, limited information focused on sex-specific differences in GC has been reported. The aim of our study was to analyze clinicopathological differences between sex groups to reveal sex disparities in GC.

Methods

We retrospectively analyzed 4722 patients with GC who underwent gastrectomy (females: 1586 (33.6 %); males: 3136 (66.4 %), and analyzed clinicopathological features between these sex groups. The overall survival (OS) rate was investigated between the two sex groups, with special reference to the pathologic World Health Organization GC classifications. Immunohistochemistry staining of sex hormone receptors, including the estrogen receptor (ER)-α, ER-β, progesterone receptor, and androgen receptor, was performed according to sex and pathological classification.

Results

Female patients were significantly associated with a younger age, poorly differentiated adenocarcinoma, and SRC compared with males. Female patients showed a significantly poorer OS than male patients, especially among those with advanced GC (AGC) aged ≤45 years. In females with AGC, those with SRC had a significantly poorer OS than those with other histologies. Moreover, the expression of ER-β was different between females and males with SRC.

Conclusions

Females with GC were significantly younger and had a different SRC histology compared with males. Furthermore, females had significantly poorer prognostic factors among young patients with SRC. Thus, young female GC patients with SRC are a main target group in which to improve prognosis.

Keywords

Gastric Cancer Overall Survival Androgen Receptor Gastric Cancer Tissue Signet Ring Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see http://www.textcheck.com/certificate/KktQd3.

Author Contribution

Hae Won Kim made substantial contributions to the conception and design of the study, analysis and interpretation of data, drafting the article, and critically revising it for important intellectual content. Jie-Hyun Kim and Beom Jin Lim made substantial contributions to the conception and design of the study, final approval of the version to be published, and agreement to be accountable for all aspects of the work. HyunKi Kim, Hoguen Kim, Jae Jun Park, Young Hoon Youn, Hyojin Park, Sung Hoon Noh, Jong Won Kim, and Seung Ho Choi critically revised the article for important intellectual content.

Funding

This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), and was funded by the Ministry of Education, Science and Technology (2012R1A1A1042417).

Disclosures

Hae Won Kim, HyunKi Kim, Hoguen Kim, Jae Jun Park, Young Hoon Youn, Hyojin Park, Sung Hoon Noh, Jong Won Kim, Seung Ho Choi, Jie-Hyun Kim and Beom Jin Lim have no disclosures to declare.

Supplementary material

10434_2016_5448_MOESM1_ESM.docx (408 kb)
Supplementary material 1 (DOCX 408 kb)

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Sipponen P, Correa P. Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiologic hypothesis. Gastric Cancer. 2002;5:213–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Qiu MZ, Wang ZQ, Zhang DS, et al. Clinicopathological characteristics and prognostic analysis of gastric cancer in the young adult in China. Tumour Biol. 2011;32:509–14.CrossRefPubMedGoogle Scholar
  4. 4.
    Jeong O, Park YK. Clinicopathological features and surgical treatment of gastric cancer in South Korea: the results of 2009 nationwide survey on surgically treated gastric cancer patients. J Gastric Cancer. 2011;11:69–77.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Huh CW, Jung da H, Kim JH, et al. Signet ring cell mixed histology may show more aggressive behavior than other histologies in early gastric cancer. J Surg Oncol. 2013;107:124–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Kwon KJ, Shim KN, Song EM, et al. Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomach. Gastric Cancer. 2014;17:43–53.CrossRefPubMedGoogle Scholar
  7. 7.
    Song M, Kang D, Yang JJ, et al. Age and sex interactions in gastric cancer incidence and mortality trends in Korea. Gastric Cancer. 2015;18:580–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Freedman ND, Chow WH, Gao YT, et al. Menstrual and reproductive factors and gastric cancer risk in a large prospective study of women. Gut. 2007;56:1671–7.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Correa P. The biological model of gastric carcinogenesis. IARC Sci Publ. 2004;(157):301–10.Google Scholar
  10. 10.
    Tian Y, Wan H, Lin Y, Xie X, Li Z, Tan G. Androgen receptor may be responsible for gender disparity in gastric cancer. Med Hypotheses. 2013;80:672–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Gan L, He J, Zhang X, et al. Expression profile and prognostic role of sex hormone receptors in gastric cancer. BMC Cancer. 2012;12:566.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010;6:195–7.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474–81.PubMedGoogle Scholar
  14. 14.
    Kominea A, Konstantinopoulos PA, Kapranos N, et al. Androgen receptor (AR) expression is an independent unfavorable prognostic factor in gastric cancer. J Cancer Res Clin Oncol. 2004;130:253–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015;47:127–41.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kim Y, Jun JK, Choi KS, Lee HY, Park EC. Overview of the National Cancer screening programme and the cancer screening status in Korea. Asian Pac J Cancer Prev. 2011;12:725–30.PubMedGoogle Scholar
  17. 17.
    Kim YS, Park HA, Kim BS, Yook JH, Lee MS. Efficacy of screening for gastric cancer in a Korean adult population: a case-control study. J Korean Med Sci. 2000;15:510–5.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Green J, Roddam A, Pirie K, Kirichek O, Reeves G, Beral V. Reproductive factors and risk of oesophageal and gastric cancer in the Million Women Study cohort. Br J Cancer. 2012;106:210–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Ando Y, Watanabe H, Fujimoto N, Ito A, Toge T. Progesterone enhancement of stomach tumor development in SD rats treated with N-methyl-N’-nitro-N-nitrosoguanidine. Jpn J Cancer Res. 1995;86:924–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Lindblad M, Rodriguez LA, Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control. 2005;16:285–94.CrossRefPubMedGoogle Scholar
  21. 21.
    Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21:20–38.CrossRefPubMedGoogle Scholar
  22. 22.
    Tokunaga A, Kojima N, Andoh T, et al. Hormone receptors in gastric cancer. Eur J Cancer Clin Oncol. 1983;19:687–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Wu CW, Tsay SH, Chang TJ, et al. Clinicopathologic comparisons between estrogen receptor-positive and -negative gastric cancers. J Surg Oncol. 1992;51:231–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Karat D, Brotherick I, Shenton BK, Scott D, Raimes SA, Griffin SM. Expression of oestrogen and progesterone receptors in gastric cancer: a flow cytometric study. Br J Cancer. 1999;80:1271–4.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Wang M, Pan JY, Song GR, Chen HB, An LJ, Qu SX. Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters. Eur J Surg Oncol. 2007;33:195–201.CrossRefPubMedGoogle Scholar
  26. 26.
    Fixemer T, Remberger K, Bonkhoff H. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate. 2003;54:79–87.CrossRefPubMedGoogle Scholar
  27. 27.
    Xu CY, Guo JL, Jiang ZN, et al. Prognostic role of estrogen receptor alpha and estrogen receptor beta in gastric cancer. Ann Surg Oncol. 2010;17:2503–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Machado JC, Carneiro F, Gartner F, Ribeiro P, Sobrinho-Simoes M. Female sex hormone receptors are not involved in gastric carcinogenesis. A biochemical and immunohistochemical study. Eur J Cancer Prev. 1994;3 Suppl 2:31–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRefPubMedGoogle Scholar
  30. 30.
    Davidson M, Okines AF, Starling N. Current and future therapies for advanced gastric cancer. Clin Colorectal Cancer. 2015;14:239–50.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2016

Authors and Affiliations

  • Hae Won Kim
    • 1
    • 4
  • Jie-Hyun Kim
    • 1
    • 4
    • 5
    Email author
  • Beom Jin Lim
    • 2
    • 4
    Email author
  • HyunKi Kim
    • 2
  • Hoguen Kim
    • 2
  • Jae Jun Park
    • 1
    • 4
  • Young Hoon Youn
    • 1
    • 4
  • Hyojin Park
    • 1
    • 4
  • Sung Hoon Noh
    • 3
  • Jong Won Kim
    • 3
    • 4
  • Seung Ho Choi
    • 3
    • 4
  1. 1.Department of Internal Medicine, Institute of GastroenterologyYonsei University College of MedicineSeoulKorea
  2. 2.Department of Pathology, Gangnam Severance HospitalYonsei University College of MedicineSeoulKorea
  3. 3.Department of Surgery, Institute of GastroenterologyYonsei University College of MedicineSeoulKorea
  4. 4.Gangnam Severance HospitalYonsei University College of MedicineSeoulKorea
  5. 5.Department of Internal Medicine, Gangnam Severance HospitalYonsei University College of MedicineSeoulKorea

Personalised recommendations